Golimumab
Tumor Necrosis Factor Blocker — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: CNTO 148, CNTO-148, simponi
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Golimumab is a drug in the Tumor Necrosis Factor Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2009. Its mechanism of action is classified as Tumor Necrosis Factor Receptor Blocking Activity. DrugCentral lists 1 molecular target, including TNF. Recorded indications include Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis and Polyarticular juvenile idiopathic arthritis.
- Drug class: Tumor Necrosis Factor Blocker.
- Mechanism of action: Tumor Necrosis Factor Receptor Blocking Activity.
- Molecular targets: TNF (1 listed in DrugCentral).
- Indications: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Polyarticular juvenile idiopathic arthritis and Psoriasis with arthropathy and others.
- ATC code: L04AB06 (Tumor necrosis factor alpha (TNF-alpha) inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (7)
- Ankylosing spondylitis
- Juvenile idiopathic arthritis
- Nonradiographic axial spondyloarthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriasis with arthropathy
- Rheumatoid arthritis
- Ulcerative colitis
Mechanism & targets
| Mechanism of action (MoA) | Tumor Necrosis Factor Receptor Blocking Activity |
|---|---|
| Established pharmacologic class | Tumor Necrosis Factor Blocker |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Tumor necrosis factor | TNF | other | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2009-10-01 | EMA | — | — | |
| 2009-04-24 | FDA | — | CENTOCOR ORTHO BIOTECH INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AB06 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Pemphigus | 5337.6 |
| Contraindicated product administered | 5192.3 |
| Glossodynia | 5191.6 |
| Systemic lupus erythematosus | 4973.9 |
| Hand deformity | 4441.5 |
| Synovitis | 4080.7 |
| Alopecia | 3953.8 |
| Arthropathy | 3923.7 |
| Swelling | 3872.5 |
| Wound | 3762.7 |
| Joint swelling | 3750.2 |
| Therapeutic product effect decreased | 3591.7 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 476181-74-5 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Golimumab used for?
DrugCentral lists the following indications for Golimumab: Ankylosing spondylitis, Juvenile idiopathic arthritis, Nonradiographic axial spondyloarthritis, Polyarticular juvenile idiopathic arthritis, Psoriasis with arthropathy, Rheumatoid arthritis and Ulcerative colitis.
How does Golimumab work?
Golimumab is classified as Tumor Necrosis Factor Receptor Blocking Activity; its molecular targets in DrugCentral include TNF.
When was Golimumab first approved?
Golimumab was first approved by the FDA in 2009.
What drug class does Golimumab belong to?
Golimumab is in the Tumor Necrosis Factor Blocker class.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4967 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201833 — compound record and bioactivity
- DrugBank DB06674 — drug record
- FDA UNII 91X1KLU43E — substance identity
- DailyMed: FDA labels for Golimumab — current prescribing information (label search)
- UniProt P01375 (TNF) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.